Orbital Drug Labs

Once primarily the domain of rockets, satellites, and astronauts, **space** is now rapidly opening its doors to a crucial new sector: **drugmakers**. This profound shift is driven by the accelerating global race for commercial **space vehicles**, creating unprecedented opportunities for **pharmaceutical innovation** in **microgravity**.

The unique **microgravity environment** of space offers significant advantages for **drug discovery**. It enables proteins to grow into larger and more uniform crystals, which is crucial for scientists to better understand the complex three-dimensional structures of disease-related proteins. This precision is vital for **drug development**, providing an accurate blueprint for how drug molecules must be shaped to achieve optimal therapeutic function.

Furthermore, **microgravity** can accelerate biological processes linked to aging, such as muscle atrophy, bone density loss, and immune dysfunction. This allows researchers to evaluate the efficacy of potential new therapies in significantly shorter timeframes, speeding up the **biopharmaceutical development** pipeline.

The **space environment** also presents an ideal setting for cultivating organoids and stem cells. Under **zero-gravity conditions**, these vital biological structures can maintain complex three-dimensional forms more effectively than under Earth’s constant gravitational pull, offering new avenues for regenerative medicine and disease modeling.

While global **pharmaceutical and biotechnology powerhouses** in regions like the United States, the European Union, Japan, and China have already established a presence in **space-based research**, Korea initially lagged. Despite this late start, the nation’s efforts to catch up are rapidly gaining momentum, with Korean companies adopting diverse and strategic approaches across the entire **space drug value chain**.

**Space LiinTech**, an innovative biotechnology startup, announced Wednesday it has commenced preliminary research under the Ministry of SMEs and Startups’ new Deep Tech Challenge Project (DCP). This initiative aims to develop an autonomous **microgravity pharmaceutical research and manufacturing platform** through a robust collaboration involving universities, research institutes, companies, and investors.

This ambitious initiative, potentially receiving up to 20 billion won ($13.2 million) in support funds, seeks to establish a sustainable infrastructure. This will allow **pharmaceutical companies** to repeatedly utilize **space for drug discovery and production**, moving beyond isolated orbital studies to a more integrated and accessible system.

“The DCP cooperation marks a pivotal beginning to advance **Space LiinTech’s** envisioned **space pharmaceutical autonomous service platform** powered by AI,” stated Yoon Harg-soon, CEO of Space LiinTech. “We are laying the essential groundwork for our **space biotechnology firms** to successfully penetrate the global market.”

Last August, Space LiinTech achieved a significant milestone by sending its self-developed Biomedical Extra-Terrestrial Enclosure — Protein Crystallization 1 (BEE-PC1), Korea’s first **space pharmaceutical research module**, to the International Space Station aboard a SpaceX Falcon 9 rocket. This automated platform successfully performed **protein crystallization experiments** without requiring astronaut intervention.

Building on this success, in November, Space LiinTech deployed BEE-1000, Korea’s first cube satellite specifically designed to conduct automated crystallization experiments involving pembrolizumab – the active ingredient in Merck’s blockbuster cancer drug, Keytruda – to Low-Earth Orbit via Korea’s Nuri space launch vehicle.

The startup plans to expand its presence in **orbital research**, scheduling three more deployments of its **space drug research platforms** this year and eight additional missions next year, with the goal of constructing a network of **microgravity laboratories**.

Meanwhile, Boryung, a more established Korean drugmaker, is strategically positioning itself to build the essential gateway to these future laboratories. The company has arguably made the most aggressive long-term investment in **space healthcare** within the country.

In 2022, Boryung announced a substantial $60 million investment in Axiom Space, a leading US company focused on developing the world’s first private space station. Further solidifying its commitment, Boryung established Brax Space in January 2024, a 51-49 joint venture with Axiom Space. This partnership secures exclusive rights to Axiom Space’s advanced technologies and future **space station infrastructure** in Korea, creating a crucial pathway for Korean players to access commercial **orbital platforms**.

Expanding its investments in **space infrastructure**, Boryung also committed $10 million in December 2024 to Intuitive Machines, a US space company renowned for designing and building lunar landers. Intuitive Machines made history in February 2024 with the first private, commercial soft landing on the Moon, marking the first US lunar landing since 1972. The Korean drugmaker further solidified this partnership by signing an agreement with Intuitive Machines to co-develop a platform for **space healthcare experiments** utilizing lunar landers and lunar terrain vehicles.

Beyond investments in **space infrastructure**, Boryung initiated its “Care In Space Challenge” in 2022, now rebranded as “Humans In Space.” This program aims to identify, fund, and accelerate startups and researchers dedicated to conducting cutting-edge **biomedical and pharmaceutical experiments in space**.

AbTis, a subsidiary of Dong-A ST specializing in advanced antibody-drug conjugate (ADC) technologies, is taking a more practical approach. The company is actively participating in a Korean government initiative to investigate whether antibodies produced under **microgravity conditions** can enhance the development of next-generation ADC therapies.

AbTis holds the critical responsibility for designing, optimizing, and evaluating ADC candidates using antibodies specifically manufactured in space. Researchers anticipate that higher-quality protein crystals and antibodies produced in **microgravity** could significantly improve the precision and efficacy of complex biologic drugs.

Despite the diverse and ambitious efforts from various **space dreamers** across the Korean **biotechnology sector**, experts emphasize the imperative need for a coordinated national strategy. This includes establishing a nationwide consortium, forging alliances with global leaders, and proactively developing essential regulations for **space biopharmaceuticals**.

“Currently, Space LiinTech and Boryung are operating independently, but there is a clear lack of a nationwide consortium that can integrate their efforts and provide comprehensive support,” commented Kim Jae-uk, a project manager at the K-Health Medical Innovation Research and Evolution.

“We urgently need to officially launch a ‘K-SpaceBio Consortium’ to maximize synergy and prevent redundant investments in this nascent field of **space biotechnology**.”

Kim further highlighted the critical need to establish a **space contract development and manufacturing organization (CDMO) ecosystem**. This would leverage Korea’s existing world-class biologics firms, such as Samsung Biologics and Celltrion, positioning the nation as a key player in **orbital biomanufacturing**.

He also advocated for the creation of a new **space biopharmaceutical-dedicated body** within the Ministry of Food and Drug Safety. Additionally, he proposed initiating discussions on **space Good Manufacturing Practice (GMP)** agenda items at the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use, aiming to establish Korea as a standard-setting nation in **space drug production**.

“The existing gap with leaders like the US and Japan can certainly be narrowed,” affirmed Kim. “The collective willingness and commitment from the government, industry, and academia will ultimately dictate the speed at which this gap is reduced and Korea emerges as a leader in **space biotechnology**.”

hwkan